Global Rare Kidney Diseases Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Rare Kidney Diseases Treatment Market is presumed to reach the market size of nearly USD 15.13 BN by 2030 from USD 7.04 BN in 2022 with a CAGR of 10.04% under the study period 2023 - 2030.

Rare kidney diseases are a group of conditions that affect the kidneys and can lead to kidney failure. They can be caused by various factors, including genetic mutations, infections, and autoimmune disorders, and may have a wide range of symptoms, including kidney damage, proteinuria, and high blood pressure. Rare kidney disease treatment often involves a combination of medications, lifestyle modifications, and dialysis or transplantation. It is often challenging due to the low prevalence and lack of knowledge about these conditions.

Market Dynamics:

The increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the rise of this field. Moreover, the growing awareness and understanding of these conditions may drive the rare kidney disease treatment market to increase. Furthermore, increased research and knowledge about rare kidney diseases have led to market growth. In addition, the increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the market's rise. However, the high cost of treatment may hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rare kidney diseases treatment. The growth and trends of rare kidney diseases treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the rare kidney diseases treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Enzyme Replacement Therapy
Monoclonal Antibodies
Others

By Indication

Fabry Disease
Atypical Hemolytic Uremic Syndrome
Lupus Nephritis
Nephropathic Cystinosis
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Sales

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Rare Kidney Diseases Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the rare kidney diseases treatment market include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals Inc., Amicus Therapeutics Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Otsuka Pharmaceutical Co. Ltd., Reata Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR11219954

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . RARE KIDNEY DISEASES TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Enzyme Replacement Therapy Historic and Forecast Sales by Regions
6.5 Monoclonal Antibodies Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Fabry Disease Historic and Forecast Sales by Regions
7.5 Atypical Hemolytic Uremic Syndrome Historic and Forecast Sales by Regions
7.6 Lupus Nephritis Historic and Forecast Sales by Regions
7.7 Nephropathic Cystinosis Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
8.5 Retail Pharmacies Historic and Forecast Sales by Regions
8.6 Online Sales Historic and Forecast Sales by Regions

9 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE RARE KIDNEY DISEASES TREATMENT COMPANIES

10.1. Rare Kidney Diseases Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF RARE KIDNEY DISEASES TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Calliditas Therapeutics AB
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. GSK plc
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Aurinia Pharmaceuticals Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Amicus Therapeutics Inc.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Shire (Takeda Pharmaceutical Company Limited)
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Sanofi
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Advicenne
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Alexion Pharmaceuticals Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Horizon Therapeutics plc
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Otsuka Pharmaceutical Co. Ltd.
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Reata Pharmaceuticals Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies